Current investigations into retatruptide peptide demonstrate notable outlook for treating weight and type diabetes. The peptide, a dual agonist of glucagon-like peptide-1 and GIP receptor, seems to present enhanced body mass and blood sugar management versus existing therapies. Ongoing clinical t